Pharmacokinetics of two dosage regimens of ciprofloxacin during a two-week therapeutic trial in patients with cystic fibrosis. 1987

H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman

Twenty-nine adult patients with cystic fibrosis received 750 or 1,000 mg of ciprofloxacin orally every 12 hours for two weeks. Pharmacokinetic data were collected on Days 1, 7, and 14. Pharmacokinetic analyses revealed minor differences between the dosage regimens, and results were similar on the first, seventh, and last day of therapy. Means for peak serum concentration (3.1 to 5.0 micrograms/ml), elimination half-life (4.8 to 5.3 hours), area under the time-concentration curve, and serum clearance (36.8 to 44.5 liter/hour) were similar to previously reported results for patients without cystic fibrosis. Sputum concentrations approximated serum values.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D012141 Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. Respiratory System Infections,Upper Respiratory Tract Infection,Upper Respiratory Tract Infections,Infections, Respiratory,Infections, Respiratory Tract,Infections, Upper Respiratory,Infections, Upper Respiratory Tract,Respiratory Infections,Upper Respiratory Infections,Infection, Respiratory System,Infection, Respiratory Tract,Respiratory Infection, Upper,Respiratory System Infection,Respiratory Tract Infection
D002939 Ciprofloxacin A broad-spectrum antimicrobial carboxyfluoroquinoline. Bay-09867,Ciprinol,Cipro,Ciprofloxacin Hydrochloride,Ciprofloxacin Hydrochloride Anhydrous,Ciprofloxacin Monohydrochloride Monohydrate,Anhydrous, Ciprofloxacin Hydrochloride,Bay 09867,Bay09867,Hydrochloride Anhydrous, Ciprofloxacin,Hydrochloride, Ciprofloxacin,Monohydrate, Ciprofloxacin Monohydrochloride,Monohydrochloride Monohydrate, Ciprofloxacin
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003550 Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION. Mucoviscidosis,Cystic Fibrosis of Pancreas,Fibrocystic Disease of Pancreas,Pancreatic Cystic Fibrosis,Pulmonary Cystic Fibrosis,Cystic Fibrosis, Pancreatic,Cystic Fibrosis, Pulmonary,Fibrosis, Cystic,Pancreas Fibrocystic Disease,Pancreas Fibrocystic Diseases
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013183 Sputum Material coughed up from the lungs and expectorated via the mouth. It contains MUCUS, cellular debris, and microorganisms. It may also contain blood or pus. Sputum, Induced,Induced Sputum,Induced Sputums,Sputums,Sputums, Induced

Related Publications

H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
January 1986, Infection,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
May 1988, Drug intelligence & clinical pharmacy,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
January 1996, Antimicrobial agents and chemotherapy,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
June 1987, Antimicrobial agents and chemotherapy,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
August 1986, Antimicrobial agents and chemotherapy,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
October 1986, Antimicrobial agents and chemotherapy,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
March 1986, Journal of clinical pharmacology,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
October 1987, The Journal of antimicrobial chemotherapy,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
May 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society,
H R Stutman, and I Shalit, and M I Marks, and R Greenwood, and S A Chartrand, and B C Hilman
December 1985, Antimicrobial agents and chemotherapy,
Copied contents to your clipboard!